8-K: Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update, Advancing Pipeline Programs

Foghorn Therapeutics announced its first quarter 2024 financial results and provided a corporate update, highlighting progress in its clinical programs and a strong cash position.

Summary

• Foghorn Therapeutics reported a net loss of $25.0 million for the first quarter of 2024, compared to a net loss of $30.5 million for the same period in 2023.
• The company's collaboration revenue was $5.1 million, slightly down from $5.3 million in the first quarter of 2023, primarily due to the termination of the Merck collaboration.
• Research and development expenses decreased to $25.5 million from $30.0 million year-over-year, mainly due to lower personnel costs.
• General and administrative expenses also decreased to $7.7 million from $8.6 million year-over-year, also due to lower personnel costs.
• As of March 31, 2024, Foghorn had $206.7 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the first half of 2026.
• The company submitted an IND for FHD-909, a first-in-class oral BRM selective inhibitor, with a Phase 1 trial planned for the second half of 2024.
• Dose escalation continues in the FHD-286 combination trial in AML, with initial clinical data expected in the second half of 2024.
• IND-enabling studies for the Selective CBP degrader program are on track to begin by year-end 2024.
• Preclinical data presented at AACR supports monotherapy activity for FHD-909, Selective CBP degrader, and Selective EP300 degrader programs.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with progress in clinical programs, a strong cash position, and promising preclinical data. However, the company is still operating at a loss and faces inherent risks in drug development.

Positives

• The company's net loss decreased year-over-year, indicating improved financial performance.
• Foghorn has a strong cash position of $206.7 million, providing a cash runway into the first half of 2026.
• The submission of the IND for FHD-909 marks a significant milestone for the company's pipeline.
• Preclinical data presented at AACR supports the potential of multiple programs, including FHD-909, Selective CBP degrader, and Selective EP300 degrader programs.
• The company is advancing multiple programs targeting historically challenging targets, demonstrating the potential of its platform.

Negatives

• Collaboration revenue decreased slightly year-over-year, primarily due to the termination of the Merck collaboration agreement.
• The company continues to operate at a loss, with a net loss of $25.0 million for the quarter.

Risks

• The company's clinical trials are subject to inherent risks and uncertainties, which could impact the timing and success of its programs.
• The company's financial performance is dependent on the success of its research and development programs and its ability to secure future collaborations and funding.
• The company faces competition from other biotechnology companies developing therapies for similar indications.
• The company's forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict.

Future Outlook

The company expects initial data from the FHD-286 combination study in AML in the second half of the year, and plans to begin a Phase 1 trial for FHD-909 in the second half of 2024. The company also anticipates initiating IND-enabling studies for the Selective CBP degrader program by year-end 2024 and has the potential for five additional INDs in the next four years.

Management Comments

• Adrian Gottschalk, President and Chief Executive Officer of Foghorn, stated that they are excited about the progress and strength of data presented this quarter, which includes robust preclinical anti-tumor monotherapy activity at tolerable doses for multiple pipeline programs.
• Mr. Gottschalk added that they believe these data demonstrate the potential of their platform to generate novel medicines against very challenging targets, as well as their leadership in the development of therapeutics in chromatin biology.
• Mr. Gottschalk also mentioned that they expect initial data from their FHD-286 combination study in AML in the second half of the year and that the IND for FHD-909 was recently submitted.

Industry Context

This announcement highlights Foghorn's progress in the competitive field of oncology drug development, particularly in the area of chromatin biology. The company's focus on novel targets and its Gene Traffic Control platform positions it as a potential leader in this space. The collaboration with Lilly also underscores the industry's interest in innovative approaches to cancer treatment.

Comparison to Industry Standards

• Foghorn's focus on chromatin biology and the development of selective inhibitors and degraders is a novel approach compared to traditional oncology drug development.
• The company's progress with FHD-909, a first-in-class BRM selective inhibitor, positions it ahead of many competitors in this specific area.
• The presentation of preclinical data at AACR for multiple programs demonstrates a commitment to scientific rigor and innovation.
• The company's cash runway into the first half of 2026 is a positive sign compared to many other biotech companies that often face funding challenges.
• While specific comparisons to other companies are not provided, the focus on novel targets and the potential for first-in-class therapies suggests a competitive advantage.

Management Changes

Stakeholder Impact

• Shareholders may view the progress in clinical programs and strong cash position positively.
• Employees may be encouraged by the company's advancements and financial stability.
• Patients may benefit from the development of new therapies for serious diseases.
• The company's collaborations with other companies may impact suppliers and partners.

Next Steps

• The company expects initial data from the FHD-286 combination study in AML in the second half of 2024.
• A Phase 1 trial for FHD-909 is planned to begin in the second half of 2024.
• IND-enabling studies for the Selective CBP degrader program are on track to begin by year-end 2024.
• Preclinical data for FHD-286 in Tyrosine Kinase Inhibitor Resistance is expected in the second quarter of 2024.

Key Dates

Keywords

Foghorn Therapeutics, FHD-286, FHD-909, AML, BRM inhibitor, CBP degrader, EP300 degrader, Oncology, Gene Traffic Control Platform, Chromatin biology, AACR, Clinical trials, IND, SMARCA2, SMARCA4